WPD Pharmaceuticals Inc. (WPDPF)
WPD Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $140. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of 0.0%. Its beta of 0.14 implies it has historically moved less than the broad market.
WPD Pharmaceuticals Inc., with its main office located in Vancouver, Canada, specializes in the discovery and development of pharmaceutical agents. The company's core mission is to advance innovative treatments for both various forms of cancer (oncology) and infectious diseases. Their active development pipeline showcases a diverse array of drug candidates: Preclinical evaluation is currently underway for WPD101, designed to combat brain cancers, including glioblastoma; WPD102, targeting Uveal Melanoma; and WPD103, which is aimed at glioblastoma multiforme. Phase 1 clinical trials are progressing for Berubicin, intended for the treatment of glioblastoma, and for WP1066, a compound addressing central nervous system tumors, pancreatic cancer, and ocular tumors. Phase I/II clinical trials are in motion for Annamycin, a potential therapy for Acute Myeloid Leukemia (AML) and the spread of cancer to the lungs (metastasis). Additionally, their portfolio includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma.
WPD Pharmaceuticals Inc. is most often compared with the following Healthcare names: